Chengdu Inno

Chengdu Inno Pharmaceutical Technology Co., Ltd. is a leading pharmaceutical research and development company based in Chengdu, China, specializing in the development of innovative drugs, improved new drugs (Class 2), and complex generics. Founded in 2011, the company has established itself as a pioneer in the Marketing Authorization Holder (MAH) system, becoming the first in Sichuan Province to obtain a B-type drug production license. Its comprehensive R&D platform covers the entire drug lifecycle, including pharmaceutical research, non-clinical and clinical studies, and commercialization. The company's portfolio features marketed products such as Carbomer Birth Canal Gel and Lansoprazole Sodium Bicarbonate Capsules, targeting therapeutic areas like obstetrics and gastroenterology. Additionally, Chengdu Inno provides integrated CRO and CDMO services, leveraging its expertise in API and formulation development to support global pharmaceutical partners. With over 100 projects in its development history, the company continues to focus on addressing unmet medical needs in cardiovascular, oncology, and nervous system disorders.